[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568044":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":61,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":26,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Beijing Chao Yang Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"New Anticoagulation Strategy Group","EXPERIMENTAL","Combination of nafamostat and unfractionated heparin for anticoagulation, adjusting the dosage of unfractionated heparin to maintain APTT in the body for 40-45 seconds, and adjusting the dosage of nafamostat to maintain APTT in the membranous lung for 50-60 seconds during ECMO",[13],"Drug: Nafamostat",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","ACTIVE_COMPARATOR","Anticoagulation with unfractionated heparin, regulating the dosage of unfractionated heparin to maintain APTT in the body for 50-60s during ECMO.",[19],"Drug: Heparin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Nafamostat","Nafamostat combined with unfractionated heparin for anticoagulation",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Heparin","unfractionated heparin for anticoagulation",[15],[32],{"name":33,"affiliation":5,"role":34},"Bing Sun, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+8613911151075","ricusunbing@126.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Bing Sun","RECRUITING","Beijing","Beijing Municipality","100020","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56,57],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"name":58,"role":37,"phone":59,"phoneExt":26,"email":60},"Li Wang, B.S.Nurs","+8615910268323","mu0mu0@yeah.net",{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100568044","a-novel-strategy-of-ecmo-management-using-nafamostat-for-regional-combined-with-low-intensity-systematic-anticoagulation-100568044",false,"NCT06676085","A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation","A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation","Inclusion Criteria:\n\n* age older than 18 years old\n* received ECMO because of severe respiratory failure\n\nExclusion Criteria:\n\n* anticoagulant contraindications\n* cerebral infarction or suspected patients\n* severe hypertension\n* women in gestational and lactational period\n* hemophilia\n* allergic to heparin or Nafamostat\n* unwilling or unable to complete the study","ALL","18 Years",{"count":73,"type":74},140,"ESTIMATED","INTERVENTIONAL",[77],"NA","ECMO is widely used in patients with refractory respiratory and\u002For circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.",[80],"ECMO","2026-06-15",{"date":83,"type":84},"2026-06-17","ACTUAL",{"date":86,"type":84},"2024-11-01",{"date":88,"type":74},"2027-12-31",{"name":5,"class":6},1]